CRISPR Therapeutics AG (CRSP) 10-Year Financial Performance & Capital Metrics

CRSP • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.Show more

Revenue $35M -90.5%
EBITDA -$447M -120.7%
Net Income -$366M -138.4%
EPS (Diluted) -4.34 -123.7%
Gross Margin -215% -431.8%
EBITDA Margin -1278.02% -2232.8%
Operating Margin -1333.05% -2116.4%
Net Margin -1046.43% -2420.5%
ROE -19.2% -134.9%
ROIC -19.5% -112.6%
Debt/Equity 0.12 -8.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 34.5% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-34.47%

3Y-66.28%

TTM-81.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-103.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM-97.53%

ROCE

10Y Avg-19.3%

5Y Avg-13.87%

3Y Avg-20.21%

Latest-21.83%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	247K	5.16M	41M	3.12M	289.59M	719K	913.08M	436K	370M	35M
Revenue Growth %	-	19.91%	6.94%	-0.92%	91.7%	-1%	1268.93%	-1%	847.62%	-0.91%
Cost of Goods Sold+	12.57M	42.24M	69.8M	113.77M	179.36M	269.41M	101.18M	110.25M	130.25M	110.25M
COGS % of Revenue	50.9%	8.18%	1.7%	36.42%	0.62%	374.7%	0.11%	252.87%	0.35%	3.15%
Gross Profit+	-12.33M	-37.07M	-28.8M	-110.65M	110.23M	-268.69M	811.9M	-109.81M	239.75M	-75.25M
Gross Margin %	-49.9%	-7.18%	-0.7%	-35.42%	0.38%	-373.7%	0.89%	-251.87%	0.65%	-2.15%
Gross Profit Growth %	-7.15%	-2.01%	0.22%	-2.84%	2%	-3.44%	4.02%	-1.14%	3.18%	-1.31%
Operating Expenses+	25.98M	73.29M	105.64M	162.07M	63.49M	85.75M	438.38M	563.35M	462.29M	391.32M
OpEx % of Revenue	105.17%	14.19%	2.58%	51.88%	0.22%	119.26%	0.48%	1292.08%	1.25%	11.18%
Selling, General & Admin	13.4M	31.06M	35.84M	48.29M	63.49M	85.75M	99.69M	102.46M	76.16M	72.98M
SG&A % of Revenue	54.26%	6.01%	0.87%	15.46%	0.22%	119.26%	0.11%	235.01%	0.21%	2.09%
Research & Development	12.57M	42.24M	69.8M	113.77M	179.36M	221.38M	340.57M	461.64M	387.33M	320.65M
R&D % of Revenue	50.9%	8.18%	1.7%	36.42%	0.62%	307.9%	0.37%	1058.82%	1.05%	9.16%
Other Operating Expenses	16K	78.51M	-197K	-5.49M	-179.36M	-221.38M	-1.88M	-762K	-1.21M	-2.31M
Operating Income+	-25.73M	-68.13M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M
Operating Margin %	-104.17%	-13.19%	-1.58%	-50.88%	0.16%	-492.96%	0.41%	-1543.95%	-0.6%	-13.33%
Operating Income Growth %	-2.88%	-1.65%	0.05%	-1.46%	1.29%	-8.58%	2.05%	-2.8%	0.67%	-1.1%
EBITDA+	-25.6M	-67.13M	-61.62M	-155.42M	51.47M	-345.25M	391.48M	-648.99M	-202.7M	-447.31M
EBITDA Margin %	-103.65%	-13%	-1.5%	-49.75%	0.18%	-480.18%	0.43%	-1488.51%	-0.55%	-12.78%
EBITDA Growth %	-2.89%	-1.62%	0.08%	-1.52%	1.33%	-7.71%	2.13%	-2.66%	0.69%	-1.21%
D&A (Non-Cash Add-back)	127K	1M	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M
EBIT	-25.71M	-14.67M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M
Net Interest Income+	-108K	-8.05M	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	-	0	0	0	0	0
Interest Expense	108K	8.05M	0	0	-	0	0	0	0	0
Other Income/Expense	-92K	45.41M	-1.96M	-5.49M	20.57M	6.38M	6M	22.66M	71.82M	103.9M
Pretax Income+	-25.82M	-22.72M	-66.61M	-164.43M	67.31M	-348.06M	379.53M	-650.5M	-150.72M	-362.67M
Pretax Margin %	-104.54%	-4.4%	-1.62%	-52.63%	0.23%	-484.08%	0.42%	-1491.97%	-0.41%	-10.36%
Income Tax+	7K	484K	1.75M	553K	448K	809K	1.87M	-325K	2.89M	3.59M
Effective Tax Rate %	1%	1.02%	1.03%	1%	0.99%	1%	1%	1%	1.02%	1.01%
Net Income+	-25.83M	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M
Net Margin %	-104.57%	-4.49%	-1.67%	-52.81%	0.23%	-485.21%	0.41%	-1491.23%	-0.42%	-10.46%
Net Income Growth %	-2.8%	0.1%	-1.95%	-1.41%	1.41%	-6.22%	2.08%	-2.72%	0.76%	-1.38%
Net Income (Continuing)	-25.83M	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-27K	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.88	-1.89	-1.71	-3.44	1.17	-5.29	4.70	-8.36	-1.94	-4.34
EPS Growth %	-2.83%	-1.15%	0.1%	-1.01%	1.34%	-5.52%	1.89%	-2.78%	0.77%	-1.24%
EPS (Basic)	-0.88	-1.89	-1.71	-3.44	1.23	-5.29	4.97	-8.36	-1.94	-4.34
Diluted Shares Outstanding	29.3M	12.26M	40.06M	47.96M	56.93M	65.95M	80.39M	77.75M	79.22M	84.36M
Basic Shares Outstanding	29.3M	12.26M	39.97M	47.96M	54.39M	65.95M	75.95M	77.75M	79.22M	84.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	156.84M	320.19M	248.38M	466.39M	987.55M	1.72B	2.42B	1.85B	1.91B	1.94B
Cash & Short-Term Investments	155.96M	315.52M	239.76M	456.65M	943.77M	1.69B	2.38B	1.82B	1.69B	1.9B
Cash Only	155.96M	315.52M	239.76M	456.65M	943.77M	1.17B	923.03M	211.88M	389.48M	298.26M
Short-Term Investments	0	0	0	0	0	521.71M	1.46B	1.6B	1.3B	1.61B
Accounts Receivable	339K	3.16M	2.63M	88K	99K	10.84M	305K	0	200M	25M
Days Sales Outstanding	500.95	223.14	23.38	10.28	0.12	5.5K	0.12	-	197.3	260.71
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	1.51M	6M	9.66M	0	0	8.4M	11.7M	6.5M	8.31M
Total Non-Current Assets+	2.58M	24.77M	22.96M	22.62M	79.2M	111.35M	334.36M	390.03M	321.49M	304.9M
Property, Plant & Equipment	1.33M	21.03M	18.86M	18.5M	72.83M	93.03M	312.04M	320.56M	305.94M	277.55M
Fixed Asset Turnover	0.19x	0.25x	2.17x	0.17x	3.98x	0.01x	2.93x	0.00x	1.21x	0.13x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	454K	399K	344K	289K	235K	180K	125K	71K	16K	0
Long-Term Investments	700K	3.15M	3.15M	3.16M	5.04M	0	0	53.13M	1.97M	0
Other Non-Current Assets	801K	3.35M	3.76M	3.83M	6.14M	18.14M	22.2M	16.27M	13.57M	27.35M
Total Assets+	159.42M	344.96M	271.35M	489.02M	1.07B	1.83B	2.75B	2.24B	2.23B	2.24B
Asset Turnover	0.00x	0.01x	0.15x	0.01x	0.27x	0.00x	0.33x	0.00x	0.17x	0.02x
Asset Growth %	103.4%	1.16%	-0.21%	0.8%	1.18%	0.71%	0.51%	-0.18%	-0.01%	0.01%
Total Current Liabilities+	10.15M	22M	14.51M	27.75M	57.11M	94.26M	119.88M	121.11M	108.79M	87.78M
Accounts Payable	1.58M	4.57M	1.64M	5.07M	5.94M	9.09M	14.82M	27.43M	38.15M	14.71M
Days Payables Outstanding	45.98	39.48	8.57	16.26	12.1	12.32	53.45	90.8	106.9	48.7
Short-Term Debt	0	0	0	0	8.49M	11.36M	12.16M	15.84M	15.63M	17.29M
Deferred Revenue (Current)	0	0	0	0	960K	1000K	1000K	0	1000K	1000K
Other Current Liabilities	9.3M	14.82M	6.97M	14.95M	25.9M	38.59M	67.51M	58.46M	33.13M	33.05M
Current Ratio	15.44x	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x
Quick Ratio	15.44x	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	113.87M	90.12M	69M	69.08M	70.22M	69.47M	232.53M	246.47M	237.98M	222.17M
Long-Term Debt	38.34M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	-64.52M	0	0	0	44.05M	50.07M	212.87M	228.18M	223.01M	206.41M
Deferred Tax Liabilities	64.52M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	542K	12.47M	12.07M	11.29M	14.39M	7.63M	7.34M	5.97M	958K	3.44M
Total Liabilities	188.55M	112.12M	83.51M	96.82M	127.33M	163.73M	352.42M	367.58M	346.77M	309.95M
Total Debt+	38.34M	0	0	0	52.54M	61.43M	225.03M	244.02M	238.63M	223.69M
Net Debt	-117.63M	-315.52M	-239.76M	-456.65M	-891.23M	-1.11B	-698M	32.14M	-150.84M	-74.56M
Debt / Equity	-	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x
Debt / EBITDA	-	-	-	-	1.02x	-	0.57x	-	-	-
Net Debt / EBITDA	-	-	-	-	-17.32x	-	-1.78x	-	-	-
Interest Coverage	-238.23x	-8.46x	-	-	-	-	-	-	-	-
Total Equity+	-29.12M	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B
Equity Growth %	-3.18%	8.99%	-0.19%	1.09%	1.4%	0.77%	0.44%	-0.22%	0%	0.03%
Book Value per Share	-0.99	19.00	4.69	8.18	16.50	25.23	29.85	24.12	23.77	22.90
Total Shareholders' Equity	-29.1M	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B
Common Stock	181K	1.22M	1.24M	1.58M	1.85M	2.28M	2.39M	2.44M	2.5M	2.7M
Retained Earnings	-33.91M	-57.08M	-125.44M	-291.57M	-224.71M	-573.58M	-195.91M	-846.09M	-999.7M	-1.37B
Treasury Stock	-4.64M	0	0	-57K	-63K	-63K	-63K	-63K	-62K	-62K
Accumulated OCI	-8K	-26K	14K	-8K	7K	-83K	-5.07M	-15.65M	1.91M	1.84M
Minority Interest	-27K	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	59.43M	-55.31M	-70.1M	-96.24M	56.68M	-238.37M	538.97M	-495.74M	-260.38M	-142.77M
Operating CF Margin %	240.6%	-10.71%	-1.71%	-30.81%	0.2%	-331.52%	0.59%	-1137.02%	-0.7%	-4.08%
Operating CF Growth %	13.4%	-1.93%	-0.27%	-0.37%	1.59%	-5.21%	3.26%	-1.92%	0.47%	0.45%
Net Income	-25.83M	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M
Depreciation & Amortization	127K	925K	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M
Stock-Based Compensation	3.68M	10.84M	18.87M	34.98M	44.06M	66.02M	102.39M	97.95M	0	86.57M
Deferred Taxes	-20K	-53.71M	0	4.28M	0	0	0	0	0	0
Other Non-Cash Items	97K	8.05M	1.75M	15.41M	-10.53M	1.86M	14.11M	12.47M	66.98M	-38.62M
Working Capital Changes	81.37M	1.78M	-25.39M	10.55M	-48.43M	33.44M	26.86M	19.84M	-193.59M	156.27M
Change in Receivables	-339K	-2.82M	531K	2.54M	-11K	-45K	-161K	305K	-200M	175M
Change in Inventory	0	-1.09M	-551.3M	332.3M	0	-25.75M	-37.51M	0	0	0
Change in Payables	0	3.86M	546.62M	-323.28M	0	25.75M	37.51M	5.16M	-20.25M	0
Cash from Investing+	-1.15M	31.88M	-8.31M	-2.77M	1.32M	-541.17M	-1.04B	-258.65M	374.65M	-280.48M
Capital Expenditures	-1.15M	-3.02M	-7.81M	-2.77M	-6.68M	-18.36M	-81.7M	-37.19M	-9.47M	-1.9M
CapEx % of Revenue	4.67%	0.58%	0.19%	0.89%	0.02%	25.53%	0.09%	85.29%	0.03%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	35M	-500K	0	8.01M	-522.81M	-953.73M	-221.47M	-2.5M	0
Cash from Financing+	96.73M	183.22M	2.61M	315.93M	430.98M	1.02B	250.94M	38.59M	62.66M	331.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-127K	-1.78M	2.61M	8.94M	15.96M	33.86M	37.68M	37.62M	0	31.29M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	58.27M	-58.33M	-77.91M	-99.01M	49.99M	-256.72M	457.27M	-532.93M	-269.85M	-144.68M
FCF Margin %	235.93%	-11.29%	-1.9%	-31.69%	0.17%	-357.06%	0.5%	-1222.31%	-0.73%	-4.13%
FCF Growth %	13.16%	-2%	-0.34%	-0.27%	1.5%	-6.14%	2.78%	-2.17%	0.49%	0.46%
FCF per Share	1.99	-4.76	-1.94	-2.06	0.88	-3.89	5.69	-6.85	-3.41	-1.71
FCF Conversion (FCF/Net Income)	-2.30x	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-22.78%	-32.5%	-56.89%	10.04%	-26.8%	18.59%	-30.42%	-8.17%	-19.2%
Return on Invested Capital (ROIC)	-	-	-	-	72.74%	-87.84%	24.81%	-27.98%	-9.17%	-19.5%
Gross Margin	-4990.28%	-717.93%	-70.26%	-3541.9%	38.06%	-37369.68%	88.92%	-25186.7%	64.8%	-215%
Net Margin	-10456.68%	-449.3%	-166.74%	-5281.08%	23.09%	-48520.86%	41.36%	-149122.71%	-41.52%	-1046.43%
Debt / Equity	-	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x
Interest Coverage	-238.23x	-8.46x	-	-	-	-	-	-	-	-
FCF Conversion	-2.30x	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x
Revenue Growth	-	1990.69%	693.9%	-92.38%	9169.85%	-99.75%	126893.18%	-99.95%	84762.39%	-90.54%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Collaboration Revenue	-	-	-	-	436K	370M	35M
Collaboration Revenue Growth	-	-	-	-	-	84762.39%	-90.54%
Grant	-	-	-	-	762K	1.21M	2.31M
Grant Growth	-	-	-	-	-	58.27%	91.87%
Exclusive License	-	-	-	900M	-	-	-
Exclusive License Growth	-	-	-	-	-	-	-
Duchenne Muscular Dystrophy License	-	151.1M	151.1M	151.1M	-	-	-
Duchenne Muscular Dystrophy License Growth	-	-	0.00%	0.00%	-	-	-
Myotonic Dystrophy Type One License	-	51.3M	51.3M	51.3M	-	-	-
Myotonic Dystrophy Type One License Growth	-	-	0.00%	0.00%	-	-	-
Collaborative Arrangement Material Rights	-	46.7M	46.7M	46.7M	-	-	-
Collaborative Arrangement Material Rights Growth	-	-	0.00%	0.00%	-	-	-
Specified Target Option Material Right	-	11.8M	11.8M	11.8M	-	-	-
Specified Target Option Material Right Growth	-	-	0.00%	0.00%	-	-	-
Collaborative Arrangement Material Rights Fourth Exclusive License	-	-	-	6.7M	-	-	-
Collaborative Arrangement Material Rights Fourth Exclusive License Growth	-	-	-	-	-	-	-
Myotonic Dystrophy Type One R And D Services	-	1.1M	1.1M	1.1M	-	-	-
Myotonic Dystrophy Type One R And D Services Growth	-	-	0.00%	0.00%	-	-	-
Waiving Of Vertexs Material Right	-	6.7M	-	-	-	-	-
Waiving Of Vertexs Material Right Growth	-	-	-	-	-	-	-
License And Service	600K	-	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

CRISPR Therapeutics AG (CRSP) reported $36.8M in revenue for fiscal year 2024.

CRISPR Therapeutics AG (CRSP) saw revenue decline by 90.5% over the past year.

CRISPR Therapeutics AG (CRSP) reported a net loss of $488.3M for fiscal year 2024.

Dividend & Returns

CRISPR Therapeutics AG (CRSP) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

CRISPR Therapeutics AG (CRSP) had negative free cash flow of $303.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

CRISPR Therapeutics AG (CRSP) 10-Year Financial Performance & Capital Metrics

CRSP • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $35M -90.5%
EBITDA -$447M -120.7%
Net Income -$366M -138.4%
EPS (Diluted) -4.34 -123.7%
Gross Margin -215% -431.8%
EBITDA Margin -1278.02% -2232.8%
Operating Margin -1333.05% -2116.4%
Net Margin -1046.43% -2420.5%
ROE -19.2% -134.9%
ROIC -19.5% -112.6%
Debt/Equity 0.12 -8.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 34.5% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-34.47%

3Y-66.28%

TTM-81.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-103.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM-97.53%

ROCE

10Y Avg-19.3%

5Y Avg-13.87%

3Y Avg-20.21%

Latest-21.83%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	247K	5.16M	41M	3.12M	289.59M	719K	913.08M	436K	370M	35M
Revenue Growth %	-	19.91%	6.94%	-0.92%	91.7%	-1%	1268.93%	-1%	847.62%	-0.91%
Cost of Goods Sold+	12.57M	42.24M	69.8M	113.77M	179.36M	269.41M	101.18M	110.25M	130.25M	110.25M
COGS % of Revenue	50.9%	8.18%	1.7%	36.42%	0.62%	374.7%	0.11%	252.87%	0.35%	3.15%
Gross Profit+	-12.33M	-37.07M	-28.8M	-110.65M	110.23M	-268.69M	811.9M	-109.81M	239.75M	-75.25M
Gross Margin %	-49.9%	-7.18%	-0.7%	-35.42%	0.38%	-373.7%	0.89%	-251.87%	0.65%	-2.15%
Gross Profit Growth %	-7.15%	-2.01%	0.22%	-2.84%	2%	-3.44%	4.02%	-1.14%	3.18%	-1.31%
Operating Expenses+	25.98M	73.29M	105.64M	162.07M	63.49M	85.75M	438.38M	563.35M	462.29M	391.32M
OpEx % of Revenue	105.17%	14.19%	2.58%	51.88%	0.22%	119.26%	0.48%	1292.08%	1.25%	11.18%
Selling, General & Admin	13.4M	31.06M	35.84M	48.29M	63.49M	85.75M	99.69M	102.46M	76.16M	72.98M
SG&A % of Revenue	54.26%	6.01%	0.87%	15.46%	0.22%	119.26%	0.11%	235.01%	0.21%	2.09%
Research & Development	12.57M	42.24M	69.8M	113.77M	179.36M	221.38M	340.57M	461.64M	387.33M	320.65M
R&D % of Revenue	50.9%	8.18%	1.7%	36.42%	0.62%	307.9%	0.37%	1058.82%	1.05%	9.16%
Other Operating Expenses	16K	78.51M	-197K	-5.49M	-179.36M	-221.38M	-1.88M	-762K	-1.21M	-2.31M
Operating Income+	-25.73M	-68.13M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M
Operating Margin %	-104.17%	-13.19%	-1.58%	-50.88%	0.16%	-492.96%	0.41%	-1543.95%	-0.6%	-13.33%
Operating Income Growth %	-2.88%	-1.65%	0.05%	-1.46%	1.29%	-8.58%	2.05%	-2.8%	0.67%	-1.1%
EBITDA+	-25.6M	-67.13M	-61.62M	-155.42M	51.47M	-345.25M	391.48M	-648.99M	-202.7M	-447.31M
EBITDA Margin %	-103.65%	-13%	-1.5%	-49.75%	0.18%	-480.18%	0.43%	-1488.51%	-0.55%	-12.78%
EBITDA Growth %	-2.89%	-1.62%	0.08%	-1.52%	1.33%	-7.71%	2.13%	-2.66%	0.69%	-1.21%
D&A (Non-Cash Add-back)	127K	1M	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M
EBIT	-25.71M	-14.67M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M
Net Interest Income+	-108K	-8.05M	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	-	0	0	0	0	0
Interest Expense	108K	8.05M	0	0	-	0	0	0	0	0
Other Income/Expense	-92K	45.41M	-1.96M	-5.49M	20.57M	6.38M	6M	22.66M	71.82M	103.9M
Pretax Income+	-25.82M	-22.72M	-66.61M	-164.43M	67.31M	-348.06M	379.53M	-650.5M	-150.72M	-362.67M
Pretax Margin %	-104.54%	-4.4%	-1.62%	-52.63%	0.23%	-484.08%	0.42%	-1491.97%	-0.41%	-10.36%
Income Tax+	7K	484K	1.75M	553K	448K	809K	1.87M	-325K	2.89M	3.59M
Effective Tax Rate %	1%	1.02%	1.03%	1%	0.99%	1%	1%	1%	1.02%	1.01%
Net Income+	-25.83M	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M
Net Margin %	-104.57%	-4.49%	-1.67%	-52.81%	0.23%	-485.21%	0.41%	-1491.23%	-0.42%	-10.46%
Net Income Growth %	-2.8%	0.1%	-1.95%	-1.41%	1.41%	-6.22%	2.08%	-2.72%	0.76%	-1.38%
Net Income (Continuing)	-25.83M	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-27K	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.88	-1.89	-1.71	-3.44	1.17	-5.29	4.70	-8.36	-1.94	-4.34
EPS Growth %	-2.83%	-1.15%	0.1%	-1.01%	1.34%	-5.52%	1.89%	-2.78%	0.77%	-1.24%
EPS (Basic)	-0.88	-1.89	-1.71	-3.44	1.23	-5.29	4.97	-8.36	-1.94	-4.34
Diluted Shares Outstanding	29.3M	12.26M	40.06M	47.96M	56.93M	65.95M	80.39M	77.75M	79.22M	84.36M
Basic Shares Outstanding	29.3M	12.26M	39.97M	47.96M	54.39M	65.95M	75.95M	77.75M	79.22M	84.36M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	156.84M	320.19M	248.38M	466.39M	987.55M	1.72B	2.42B	1.85B	1.91B	1.94B
Cash & Short-Term Investments	155.96M	315.52M	239.76M	456.65M	943.77M	1.69B	2.38B	1.82B	1.69B	1.9B
Cash Only	155.96M	315.52M	239.76M	456.65M	943.77M	1.17B	923.03M	211.88M	389.48M	298.26M
Short-Term Investments	0	0	0	0	0	521.71M	1.46B	1.6B	1.3B	1.61B
Accounts Receivable	339K	3.16M	2.63M	88K	99K	10.84M	305K	0	200M	25M
Days Sales Outstanding	500.95	223.14	23.38	10.28	0.12	5.5K	0.12	-	197.3	260.71
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	1.51M	6M	9.66M	0	0	8.4M	11.7M	6.5M	8.31M
Total Non-Current Assets+	2.58M	24.77M	22.96M	22.62M	79.2M	111.35M	334.36M	390.03M	321.49M	304.9M
Property, Plant & Equipment	1.33M	21.03M	18.86M	18.5M	72.83M	93.03M	312.04M	320.56M	305.94M	277.55M
Fixed Asset Turnover	0.19x	0.25x	2.17x	0.17x	3.98x	0.01x	2.93x	0.00x	1.21x	0.13x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	454K	399K	344K	289K	235K	180K	125K	71K	16K	0
Long-Term Investments	700K	3.15M	3.15M	3.16M	5.04M	0	0	53.13M	1.97M	0
Other Non-Current Assets	801K	3.35M	3.76M	3.83M	6.14M	18.14M	22.2M	16.27M	13.57M	27.35M
Total Assets+	159.42M	344.96M	271.35M	489.02M	1.07B	1.83B	2.75B	2.24B	2.23B	2.24B
Asset Turnover	0.00x	0.01x	0.15x	0.01x	0.27x	0.00x	0.33x	0.00x	0.17x	0.02x
Asset Growth %	103.4%	1.16%	-0.21%	0.8%	1.18%	0.71%	0.51%	-0.18%	-0.01%	0.01%
Total Current Liabilities+	10.15M	22M	14.51M	27.75M	57.11M	94.26M	119.88M	121.11M	108.79M	87.78M
Accounts Payable	1.58M	4.57M	1.64M	5.07M	5.94M	9.09M	14.82M	27.43M	38.15M	14.71M
Days Payables Outstanding	45.98	39.48	8.57	16.26	12.1	12.32	53.45	90.8	106.9	48.7
Short-Term Debt	0	0	0	0	8.49M	11.36M	12.16M	15.84M	15.63M	17.29M
Deferred Revenue (Current)	0	0	0	0	960K	1000K	1000K	0	1000K	1000K
Other Current Liabilities	9.3M	14.82M	6.97M	14.95M	25.9M	38.59M	67.51M	58.46M	33.13M	33.05M
Current Ratio	15.44x	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x
Quick Ratio	15.44x	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	113.87M	90.12M	69M	69.08M	70.22M	69.47M	232.53M	246.47M	237.98M	222.17M
Long-Term Debt	38.34M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	-64.52M	0	0	0	44.05M	50.07M	212.87M	228.18M	223.01M	206.41M
Deferred Tax Liabilities	64.52M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	542K	12.47M	12.07M	11.29M	14.39M	7.63M	7.34M	5.97M	958K	3.44M
Total Liabilities	188.55M	112.12M	83.51M	96.82M	127.33M	163.73M	352.42M	367.58M	346.77M	309.95M
Total Debt+	38.34M	0	0	0	52.54M	61.43M	225.03M	244.02M	238.63M	223.69M
Net Debt	-117.63M	-315.52M	-239.76M	-456.65M	-891.23M	-1.11B	-698M	32.14M	-150.84M	-74.56M
Debt / Equity	-	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x
Debt / EBITDA	-	-	-	-	1.02x	-	0.57x	-	-	-
Net Debt / EBITDA	-	-	-	-	-17.32x	-	-1.78x	-	-	-
Interest Coverage	-238.23x	-8.46x	-	-	-	-	-	-	-	-
Total Equity+	-29.12M	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B
Equity Growth %	-3.18%	8.99%	-0.19%	1.09%	1.4%	0.77%	0.44%	-0.22%	0%	0.03%
Book Value per Share	-0.99	19.00	4.69	8.18	16.50	25.23	29.85	24.12	23.77	22.90
Total Shareholders' Equity	-29.1M	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B
Common Stock	181K	1.22M	1.24M	1.58M	1.85M	2.28M	2.39M	2.44M	2.5M	2.7M
Retained Earnings	-33.91M	-57.08M	-125.44M	-291.57M	-224.71M	-573.58M	-195.91M	-846.09M	-999.7M	-1.37B
Treasury Stock	-4.64M	0	0	-57K	-63K	-63K	-63K	-63K	-62K	-62K
Accumulated OCI	-8K	-26K	14K	-8K	7K	-83K	-5.07M	-15.65M	1.91M	1.84M
Minority Interest	-27K	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	59.43M	-55.31M	-70.1M	-96.24M	56.68M	-238.37M	538.97M	-495.74M	-260.38M	-142.77M
Operating CF Margin %	240.6%	-10.71%	-1.71%	-30.81%	0.2%	-331.52%	0.59%	-1137.02%	-0.7%	-4.08%
Operating CF Growth %	13.4%	-1.93%	-0.27%	-0.37%	1.59%	-5.21%	3.26%	-1.92%	0.47%	0.45%
Net Income	-25.83M	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M
Depreciation & Amortization	127K	925K	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M
Stock-Based Compensation	3.68M	10.84M	18.87M	34.98M	44.06M	66.02M	102.39M	97.95M	0	86.57M
Deferred Taxes	-20K	-53.71M	0	4.28M	0	0	0	0	0	0
Other Non-Cash Items	97K	8.05M	1.75M	15.41M	-10.53M	1.86M	14.11M	12.47M	66.98M	-38.62M
Working Capital Changes	81.37M	1.78M	-25.39M	10.55M	-48.43M	33.44M	26.86M	19.84M	-193.59M	156.27M
Change in Receivables	-339K	-2.82M	531K	2.54M	-11K	-45K	-161K	305K	-200M	175M
Change in Inventory	0	-1.09M	-551.3M	332.3M	0	-25.75M	-37.51M	0	0	0
Change in Payables	0	3.86M	546.62M	-323.28M	0	25.75M	37.51M	5.16M	-20.25M	0
Cash from Investing+	-1.15M	31.88M	-8.31M	-2.77M	1.32M	-541.17M	-1.04B	-258.65M	374.65M	-280.48M
Capital Expenditures	-1.15M	-3.02M	-7.81M	-2.77M	-6.68M	-18.36M	-81.7M	-37.19M	-9.47M	-1.9M
CapEx % of Revenue	4.67%	0.58%	0.19%	0.89%	0.02%	25.53%	0.09%	85.29%	0.03%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	35M	-500K	0	8.01M	-522.81M	-953.73M	-221.47M	-2.5M	0
Cash from Financing+	96.73M	183.22M	2.61M	315.93M	430.98M	1.02B	250.94M	38.59M	62.66M	331.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-127K	-1.78M	2.61M	8.94M	15.96M	33.86M	37.68M	37.62M	0	31.29M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	58.27M	-58.33M	-77.91M	-99.01M	49.99M	-256.72M	457.27M	-532.93M	-269.85M	-144.68M
FCF Margin %	235.93%	-11.29%	-1.9%	-31.69%	0.17%	-357.06%	0.5%	-1222.31%	-0.73%	-4.13%
FCF Growth %	13.16%	-2%	-0.34%	-0.27%	1.5%	-6.14%	2.78%	-2.17%	0.49%	0.46%
FCF per Share	1.99	-4.76	-1.94	-2.06	0.88	-3.89	5.69	-6.85	-3.41	-1.71
FCF Conversion (FCF/Net Income)	-2.30x	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-22.78%	-32.5%	-56.89%	10.04%	-26.8%	18.59%	-30.42%	-8.17%	-19.2%
Return on Invested Capital (ROIC)	-	-	-	-	72.74%	-87.84%	24.81%	-27.98%	-9.17%	-19.5%
Gross Margin	-4990.28%	-717.93%	-70.26%	-3541.9%	38.06%	-37369.68%	88.92%	-25186.7%	64.8%	-215%
Net Margin	-10456.68%	-449.3%	-166.74%	-5281.08%	23.09%	-48520.86%	41.36%	-149122.71%	-41.52%	-1046.43%
Debt / Equity	-	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x
Interest Coverage	-238.23x	-8.46x	-	-	-	-	-	-	-	-
FCF Conversion	-2.30x	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x
Revenue Growth	-	1990.69%	693.9%	-92.38%	9169.85%	-99.75%	126893.18%	-99.95%	84762.39%	-90.54%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Collaboration Revenue	-	-	-	-	436K	370M	35M
Collaboration Revenue Growth	-	-	-	-	-	84762.39%	-90.54%
Grant	-	-	-	-	762K	1.21M	2.31M
Grant Growth	-	-	-	-	-	58.27%	91.87%
Exclusive License	-	-	-	900M	-	-	-
Exclusive License Growth	-	-	-	-	-	-	-
Duchenne Muscular Dystrophy License	-	151.1M	151.1M	151.1M	-	-	-
Duchenne Muscular Dystrophy License Growth	-	-	0.00%	0.00%	-	-	-
Myotonic Dystrophy Type One License	-	51.3M	51.3M	51.3M	-	-	-
Myotonic Dystrophy Type One License Growth	-	-	0.00%	0.00%	-	-	-
Collaborative Arrangement Material Rights	-	46.7M	46.7M	46.7M	-	-	-
Collaborative Arrangement Material Rights Growth	-	-	0.00%	0.00%	-	-	-
Specified Target Option Material Right	-	11.8M	11.8M	11.8M	-	-	-
Specified Target Option Material Right Growth	-	-	0.00%	0.00%	-	-	-
Collaborative Arrangement Material Rights Fourth Exclusive License	-	-	-	6.7M	-	-	-
Collaborative Arrangement Material Rights Fourth Exclusive License Growth	-	-	-	-	-	-	-
Myotonic Dystrophy Type One R And D Services	-	1.1M	1.1M	1.1M	-	-	-
Myotonic Dystrophy Type One R And D Services Growth	-	-	0.00%	0.00%	-	-	-
Waiving Of Vertexs Material Right	-	6.7M	-	-	-	-	-
Waiving Of Vertexs Material Right Growth	-	-	-	-	-	-	-
License And Service	600K	-	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

CRISPR Therapeutics AG (CRSP) reported $36.8M in revenue for fiscal year 2024.

CRISPR Therapeutics AG (CRSP) saw revenue decline by 90.5% over the past year.

CRISPR Therapeutics AG (CRSP) reported a net loss of $488.3M for fiscal year 2024.

Dividend & Returns

CRISPR Therapeutics AG (CRSP) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

CRISPR Therapeutics AG (CRSP) had negative free cash flow of $303.1M in fiscal year 2024, likely due to heavy capital investments.